Related Experiment Video

Updated: May 17, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents

Alessandro Finkelsztejn1, Alberto Alain Gabbai, Yara Dadalti Fragoso

  • 1Department of Neurology, Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brazil. alessandro.finkels@gmail.com

Arquivos De Neuro-Psiquiatria
|October 13, 2012
PubMed

Insights

Latin American experts developed new multiple sclerosis (MS) treatment guidelines addressing regional challenges. These evidence-based recommendations improve access to disease-modifying therapies for MS patients in Latin America.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) affects approximately 50,000 individuals in Latin America.
  • Existing European and North American treatment algorithms do not adequately address regional healthcare access and treatment challenges.

Framework:

  • The Latin American Multiple Sclerosis Forum, an independent expert group, convened to address these disparities.
  • The Forum evaluated scientific evidence on the efficacy and safety of disease-modifying treatments (DMTs).

Implementation:

  • Analysis included treatment access and pharmacovigilance programs across eight represented Latin American countries.
  • A tailored set of evidence-based guidelines specifically for Latin America was developed.

Implications:

  • This initiative provides region-specific recommendations for multiple sclerosis management.
  • The guidelines aim to enhance patient access to appropriate and effective DMTs.
  • Future perspectives for multiple sclerosis treatment in Latin America were also discussed.
Abstract

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...